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Abstract
Background: Interferon-γ release assays (IGRA) with Resuscitation promoting factor (Rpf) proteins enhanced
tuberculosis (TB) screening and diagnosis in adults but have not been evaluated in children. Children often develop
paucibacillary TB and their immune response differs from that of adults, which together affect TB disease
diagnostics and immunodiagnostics. We assessed the ability of Rpf to identify infection among household TB-
exposed children in The Gambia and investigated their ability to discriminate Mycobacterium tuberculosis complex
(MTBC) infection from active TB disease in children.
Methods: Detailed clinical investigations were done on 93 household TB-exposed Gambian children and a
tuberculin skin test (TST) was administered to asymptomatic children. Venous blood was collected for overnight
stimulation with ESAT-6/CFP-10-fusion protein (EC), purified protein derivative and RpfA, B, C, D and E. Interferon
gamma (IFN-γ) production was measured by ELISA in supernatants and corrected for the background level.
Infection status was defined by IGRA with EC and TB disease by mycobacterial confirmation and/or clinical
diagnosis. We compared IFN-γ levels between infected and uninfected children and between infected and TB
diseased children using a binomial logistic regression model while correcting for age and sex. A Receiver Operating
Characteristics analysis was done to find the best cut-off for IFN-γ level and calculate sensitivity and specificity.
Results: Interferon gamma production was significantly higher in infected (IGRA+, n = 45) than in uninfected (IGRA-,
n = 20) children after stimulation with RpfA, B, C, and D (P = 0.03; 0.007; 0.03 and 0.003, respectively). Using RpfB and
D-specific IFN-γ cut-offs (33.9 pg/mL and 67.0 pg/mL), infection was classified with a sensitivity-specificity
combination of 73–92% and 77–72% respectively, which was similar to and better than 65–75% for TST. Moreover,
IFN-γ production was higher in infected than in TB diseased children (n = 28, 5 bacteriologically confirmed, 23
clinically diagnosed), following RpfB and D stimulation (P = 0.02 and 0.03, respectively).
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Conclusion: RpfB and RpfD show promising results for childhood MTBC infection screening, and both performed
similar to and better than the TST in our study population. Additionally, both antigens appear to discriminate
between infection and disease in children and thus warrant further investigation as screening and diagnostic
antigens for childhood TB.
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Background
About 10% of new and relapse tuberculosis (TB) cases
occur in children under 15 years of age; accounting for
at least 1 million cases a year [1]. Identifying and treat-
ing TB in children forms an essential part of TB control
but detecting infection and diagnosing paediatric TB are
challenging. Principally due to its paucibacillary nature,
microbiological diagnosis of TB disease in children is in-
sensitive. Hence, diagnosis is mainly based on clinical
symptoms, which resemble those of other respiratory
diseases [2]. Screening for Mycobacterium tuberculosis
complex (MTBC) infection is done by the widely imple-
mented tuberculin skin test (TST) or the interferon
gamma (IFN-γ) release assay (IGRA), both assessing the
host’s cell mediated immune response to tuberculous
antigens [3]. Both tests have their limitations [4]. The
TST –employing purified protein derivative (PPD) as
antigen—has a low specificity due to cross reactivity with
Bacillus Calmette-Guérin (BCG) vaccination and expos-
ure to non-pathogenic environmental mycobacteria [5].
The IGRA –employing antigens 6 kDa early secretory
antigenic target (ESAT-6) and 10 kDa culture filtrate
(CFP-10) (EC) as peptide pool or as fusion protein—is
less sensitive for detection of M. africanum (Maf) infec-
tion compared to the classical M. tuberculosis (Mtb)
sensu stricto strains infection [6]; particularly important
for countries like The Gambia where up to half of
MTBC infections are caused by Maf strains [7]. Both the
TST and IGRA cannot distinguish between infection
and TB disease or individuals with high risk of progres-
sing towards TB disease [8, 9]. These separations are im-
portant, as patients need to receive timely and
appropriate treatment.
Evaluating new antigens for stimulation assays might
solve the issues with sensitivity and specificity for MTBC
infection screening. Antigens of recent interest are Re-
suscitation promoting factors (Rpf); secreted bacterial
proteins initially characterized by their capacity to resus-
citate nonreplicating cells in vitro and in vivo through
lysozyme and peptidoglycan hydrolase activities [10]. Re-
suscitation promoting factors are specifically secreted by
mycobacteria that shift from a dormant to their active
replicating stage, in which they cause symptomatic dis-
ease [11, 12]. Five homologous Rpf genes (Rv0867c
(RpfA); Rv1009 (RpfB); Rv1884c (RpfC); Rv2389c (RpfD);
Rv2450c (RpfE)) have been identified in the genome of
several mycobacteria, including Mtb, Maf and BCG [12,
13]. Resuscitation promoting factor A-, D- and E-
specific IFN-γ responses in adults differ between in-
fected and TB diseased individuals [14, 15]. Moreover,
Huang et al found that the IFN-γ response to RpfA and
D was associated with different levels of TB exposure
and that it could possibly predict progression towards
active disease in adults [16].
To the best of our knowledge, Rpf-specific IFN-γ re-
sponses have not previously been evaluated in children
and could potentially be employed to improve childhood
TB screening and diagnostics. We assessed the ability of
Rpf to detect MTBC infection and to discriminate infec-
tion from TB disease among household-exposed chil-
dren in The Gambia.
Methods
Study population and ethics
This study was approved by the MRC/Gambian govern-
ment joint ethics committee. From January to December
2017, children aged below 15 years who were permanent
household contacts of an adult smear-positive index TB
case were recruited into the study. Written informed
consent was obtained from the parents/guardians of the
children prior to inclusion into the study.
Clinical examination
Symptom screening was performed with a standard
questionnaire including cough, fatigue, haemoptysis,
weight loss, fever, neck swelling, night sweats and
wheezing. Participants were considered symptomatic if
persistent unremitting cough of ≥2 weeks duration was
reported, with at least one other symptom as described
before [17]. A TST was performed on all asymptomatic
children, using the Mantoux method (2 tuberculin units,
PPD RT23 Statens Serum Institut, Denmark), and indur-
ation size was read 48–72 h later. A skin induration of
≥10mm measured transversely was considered TST
positive (TST+), in line with WHO recommendations
[18]. To save the scarce and expensive PPD antigens for
children that needed it most, children that were consid-
ered symptomatic did not receive a TST. All children
that were either TST+ or symptomatic underwent
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detailed clinical evaluation in the MRC clinic, including
HIV testing and a chest X-ray as described before [17].
Sample collection
Sputum was collected from all participants that were
symptomatic and/or had an abnormal chest X-ray, either
spontaneously or induced in children who were unable
to expectorate. Samples were used for sputum micros-
copy, MTB/RIF assay (GeneXpert, Cepheid) and myco-
bacterial liquid culture in the MGIT BACTEC
instrument (Becton-Dickinson). All culture positive sam-
ples were genotyped using the spoligotyping method.
For each adult TB index case up to 3 TST- and 3 TST+
children living within their household were included in
this study. Venous blood (5 mL) was collected in a hepa-
rinized tube and stimulated with antigens within 4 h of
collection. The laboratory team was blinded to all clin-
ical information of the participants.
Rpf antigens
Recombinant RpfA-E were kindly provided by Leiden
University Medical Centre, The Netherlands and pro-
duced as previously described [19]. The antigens were
freeze-dried and shipped at room temperature. The
same batch of antigens was used throughout the study.
Whole blood stimulation assay and IGRA
Heparinized whole blood was stimulated on a U-bottom
96-well plate in duplicate with and without stimulant.
According to blood volume available, the antigens in-
cluded RpfA-E (final concentration 10 μg/mL) [16], PPD
(final concentration 10 μg/mL, RT23, Statens Serum In-
stitute, Denmark), ESAT-6/CFP-10 (EC)-fusion protein
(final concentration 10 μg/mL) [3, 20–22], Phytohem-
agglutinin Antigen-L (PHA-L, final concentration 10 μg/
mL, Sigma Aldrich, USA) in RPMI-1640 medium (com-
plemented with Penicillin and Streptomycin, final con-
centration 100 U/mL Penicillin, 100 μg/mL
Streptomycin, Gibco Invitrogen, USA) to a final volume
of 100 μl/well. Plates were incubated for 18–22 h at
37 °C, 5% CO2, followed by harvesting and freezing the
supernatants at − 20 °C. The IFN-γ concentration in the
supernatants was quantified with enzyme-linked im-
munosorbent assay (ELISA) (in-house ELISA, performed
as described before [21]) and the optical density (OD)
was read at 450 nm (Softmax Pro plate reader). Concen-
trations were calculated with a four-parameter curve fit
(Softmax Pro software). The IGRA cut-off was set to
124.2 pg/mL, derived from the IFN-γ concentration
mean of all unstimulated samples plus two times stand-
ard deviation [21, 23]. EC-specific IFN-γ levels above the
cut-off were considered IGRA positive (IGRA+).
Definition of MTBC infection and TB disease
All participants that were IGRA+ were defined as
“MTBC infected” and all IGRA negative (IGRA-) partici-
pants as “MTBC uninfected”. “TB disease” was defined
by mycobacterial confirmation and/or clinical diagnosis
(i.e., suggestive appearance on chest radiograph, no re-
sponse to empirical broad-spectrum antibiotics or
favourable response to anti-tuberculous therapy), as de-
scribed before [21].
Data analysis
Categorical data were reported as frequency and propor-
tions. Medians and interquartile ranges (IQRs) were cal-
culated for non-normally distributed continuous data.
IFN-γ levels were corrected to antigen specific responses
by subtracting the IFN-γ level in the unstimulated con-
trol (i.e., baseline IFN-γ level). Continuous TST (in mm)
and IGRA (in IFN-γ concentration) results were com-
pared using Spearman’s rank correlation. Binomial TST,
IGRA and TB disease status results were compared with
age (in years) using a Mann Whitney U-test and with
sex using a two-tailed Fisher’s test. For every antigen, ln
(IFN-γ) (natural logarithm transformation) was com-
pared between the different infection/disease groups
with a binomial logistic regression model while correct-
ing for age and sex. The log-transformation was done to
minimise skewed distributions of IFN-y concentrations.
Significance level was p < 0.05. A Bonferroni correction
was used to correct for multiple testing of 5 antigens of
interest. P-values < 0.01 were considered highly signifi-
cant (0.05/5 = 0.01). Antigens that induced highly signifi-
cant differences were further investigated: a Receiver
Operating Characteristic (ROC) curve was produced for
varying infection/disease classifications with the Rpf-
specific IFN-γ values. The area under the curve (AUC)
of the ROC plots was calculated and an ideal cut-off was
chosen using the Youden Index [24]. R version 3.2.3 was
used for all analysis, specifically package stats for logistic
regression analysis and package ROCR for ROC-curve
analysis.
Results
Study participant demographics, TST screening and TB
disease diagnosis
A total of 93 children all tested HIV-negative were in-
cluded in this study with a median (IQR) age of 8.0
(4.7–10.9) years and 47 (50.5%) were female. Forty-three
(43; 46.2%) children were symptomatic with a median
(IQR) age of 9.7 (6.2–12.0). A BCG scar was present in
61 out of 66 (92.4%) assessed children. TB disease was
diagnosed in 28 (30.1%) children (5 cases were bacterio-
logically confirmed TB all of the M. tuberculosis Euro-
American lineage also called Mtb-lineage 4 and clinically
diagnosed TB were 23 cases) (Fig. 1). The remaining 15
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children were deemed to have other respiratory diseases.
Fifty children (all asymptomatic) received the Mantoux
test (tuberculin skin test; TST) and 26 (52.0%) were
TST+.
IGRA results and MTBC infection
To define MTBC infection status of the study partici-
pants, the EC-fusion protein IGRA result was taken as
gold standard, with IFN-γ cut-off 124.2 pg/mL. Overall,
EC-fusion protein induced a high IFN-γ response in all
study participants (median (IQR) 275.5 (74.7–1435.0)
pg/mL). Among the 65 children without TB disease
(asymptomatic or symptomatic), 45 (70.3%) were
IGRA+.
Comparison of TST and IGRA results, and age within the
subgroups
Among the 50 children who received a TST, 22 (44.0%)
were TST + IGRA+, 12 (24.0%) were TST-IGRA- and 16
children had discordant results (Fig. 1). Tuberculin skin
test and IGRA results (in mm skin induration and IFN-γ
levels, respectively) were correlated (Spearman’s ρ 0.4;
P < 0.001) [see Additional file 1, Supplementary Figure
1]. Tuberculin skin test+ children were older than TST-
children (median (IQR) 7.5 (5.0–8.8) years versus 4.0
(3.0–7.3) years; P = 0.05) [see Additional file 1, Supple-
mentary Figure 2]. There was a borderline age difference
between IGRA+ (infected) and IGRA- (uninfected) chil-
dren (median (IQR) 8.0 (5.0–10.0) years versus 4.5 (3.0–
8.0) years; P = 0.06) [see Additional file 1, Supplementary
Figure 3]. TB diseased children were significantly older
than children without TB disease (irrespective of infec-
tion status) (median (IQR) 9.7 (6.0–12.2) years versus
7.0 (4.0–9.0) years, P = 0.02). There was no difference in
age between children with bacteriologically confirmed
and clinically diagnosed TB disease. We observed a
trend of TB disease and infection in older children com-
pared to younger children, which aligns with the slow
progression to nature of MTBC infection. Resuscitation
promoting factor-specific IFN-γ responses did not differ
between children age below 5 years and above 5 years,
and there was no correlation between Rpf-specific IFN-γ
levels and age in years (data not shown).
IFN-γ response to RpfA-D in MTBC infected compared to
uninfected children without TB disease
Whole blood stimulation with Rpf induced significantly
higher IFN-γ responses in the infected (IGRA+) com-
pared to the uninfected (IGRA-) children among those
without TB disease. The medium (IQR) IFN-γ level of
infected versus uninfected children was 34.6 (5.2–73.0)
pg/mL versus 3.0 (0.0–11.1) pg/mL (P = 0.03) for RpfA,
77.4 (21.3–235.7) pg/mL versus 13.6 (0.0–31.6) pg/mL
(P = 0.007) for RpfB, 45.0 (25.9–115.8) pg/mL versus
24.9 (0.0–30.4) pg/mL (P = 0.03) for RpfC, and 138.0
(67.5–340.5) pg/mL versus 49.3 (16.3–105.1) pg/mL
(P = 0.004) for RpfD (see Fig. 2). Purified protein deriva-
tive induced a higher IFN-γ response in infected chil-
dren (medium (IQR) 1078.9 (113.1–3937.8) pg/mL
versus 92.7 (3.8–350.1) pg/mL, P = 0.01).
Performance of RpfB and D in an IGRA-based test for
screening MTBC infection
In our quest for a suitable alternative screening antigen,
RpfB and D were found to induce the most differential
IFN-γ response (P < 0.01; Fig. 2). This result motivated
our decision to further analyse their discriminatory cap-
acity using ROC-curves. The area under the curves
Fig. 1 Flow diagram of all participants per screening category included in the study. TST: tuberculin skin test; IGRA: interferon gamma release
assay; TB: tuberculosis; EC: ESAT-6/CFP-10 fusion protein
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(AUC) were 0.77 and 0.74 for RpfB and RpfD, respectively
(Fig. 3). Based on the Youden Index, a cut-off at 33.9 pg/
mL for RpfB-specific IFN-γ levels was derived, leading to
73% (24/33) sensitivity and 92% (12/13) specificity (Fig. 3).
Similarly, for RpfD, a cut-off of 67.0 pg/mL led to 77%
(33/43) sensitivity and 72% (13/18) specificity (Fig. 3). For
the TST, these figures were 65% (22/34) sensitivity and
75% (12/16) specificity (Fig. 1).
In contrast, when using TST results as standard only
the stimulations with EC-fusion protein and PPD induced
a significantly different IFN-γ response between infected
and uninfected groups (P = 0.004 and 0.003 respectively
[see Additional file 1, Supplementary Figure 4]).
IFN-γ response to RpfB and D in MTBC infected compared
to diseased children
Since RpfB and D responses could discriminate between
infected and uninfected children, we evaluated the
diagnostic performance of TB disease. Resuscitation pro-
moting factor B and D induced a significantly higher
IFN-γ response in infected compared to TB diseased
children (medium (IQR) 47.1 (7.1–129.8) pg/mL versus
9.1 (0.0–75.3) pg/mL, P = 0.02 and 91.1 (40.9–284.5) pg/
mL versus 60.1 (11.0–114.2) pg/mL, P = 0.03) respect-
ively (Fig. 2). EC-fusion protein induced higher IFN-γ re-
sponses in infected compared to TB diseased children
(P = 0.0002), but no significant difference was obtained
with PPD stimulation between these groups (Fig. 2).
There was no significant difference in IFN-γ response
between uninfected and TB diseased children for any of
the Rpf antigens, EC or PPD (Fig. 2).
Background IFN-γ response in TB diseased children
compared to children without TB disease
In general, TB diseased children had significantly higher
background IFN-γ responses (whole blood stimulated
Fig. 2 IFN-γ response after ex vivo whole blood antigen stimulation. The first panel (a) “medium” depicts the results of the unstimulated assays,
i.e., the background level. The other panels (b-h) represent the respective antigen-stimulated assays. Solid lines: median IFN- γ values per infection
category. IFN-γ concentrations were corrected for the background signal (value of unstimulated IFN-γ level subtracted), except for the results in
the first panel “medium”. All values above 4000 were set to 4000 pg/mL. P-values below 0.05 indicated. P-values were derived from logistic
regression models including possible confounders age and sex, after log-transformation of the IFN-γ variable. IGRA: IFN-γ release assay; EC: Esat-6/
CFP-10; PPD: Purified protein derivative; Rpf: Resuscitation promoting factor
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with medium alone) compared to the other children
without TB disease (irrespective of their infection status)
(medium (IQR) 52.6 (42.0–78.4) pg/mL versus 18.6
(0.0–41.7) pg/mL, P = 0.0003) (Fig. 2). Using an ROC-
curve, we further analysed the medium background re-
sponse as a screening and/or diagnosis tool in our study
setting. The AUC was 0.77, and at optimal cut-off 33.3
mg/mL (based on the Youden Index), sensitivity and
specificity were 92.9 and 63.1%, respectively [see Add-
itional file 1, Supplementary Figure 5].
Discussion
We found that Rpf-specific IFN-γ responses are associ-
ated with MTBC infection status in household-exposed
children in The Gambia. This suggests that Rpf are at-
tractive antigens to consider for childhood TB screening
and diagnostics. Screening for infection and diagnosing
TB disease represent core challenges in paediatric TB,
particularly in low- and middle-income countries, where
TB prevalence is high and other paediatric illnesses with
TB-resembling symptoms are common. Given the
worldwide shortage of PPD for tuberculin skin testing
and its inherent lack of sensitivity and specificity [25], it
is essential to develop new methods for MTBC infection
screening, particularly for the high-risk group of
household-exposed children of infectious adult TB pa-
tients, as recommended by the WHO.
We stimulated children’s venous blood samples
in vitro with Rpf antigens and showed that RpfB and D
induce lower IFN-γ responses in uninfected children
compared to infected children. In our study population,
RpfB and RpfD -based IGRAs identified infection with
higher sensitivity than a TST. This is in line with previ-
ous studies in adults. In a multi-side study in adults in-
cluding The Gambia, Sutherland et al showed that
soluble IFN-γ responses after 7 days whole blood stimu-
lation with RpfA and RpfE but not RpfB were higher in
TST+ than TST- participants without TB disease [14].
Similarly, Huang et al reported that RpfA and RpfD in-
duced higher IFN-γ responses in “latent tuberculosis in-
fected” (LTBI) household adult contacts compared to
community exposed infected participants and healthy
controls [16]. Commandeur et al also found that RpfA
and RpfD induced different immune responses in vitro
in infected adults than in healthy controls [26]. There
are clear differences in the discriminatory capacity of the
different Rpf proteins in the highlighted previous studies
in adults. However, RpfA-induced responses consistently
differ between infected and uninfected adults across
multiple studies. An explanation for the absence of
strong discriminatory RpfA-induced IFN-γ responses in
our experiments could be given by the experimental set-
up. Our study that focussed on exploring the possibility
of integrating Rpf in TB screening, investigated a short-
term stimulation of ~ 20 h, contrary to previous studies,
Fig. 3 ROC-curves for RpfB and RpfD in an IGRA-based screening for MTBC infection. IGRA+ participants were classified as infected and IGRA-
participants were classified as uninfected. AUC’s for RpfB and D are 0.77 and 0.74, respectively. Cut-off values for IFN-γ levels were based on the
Youden Index. For RpfB, a cut-off at 33.9 pg/mL led to 73% sensitivity and 92% specificity. For RpfD, a cut-off of 67.0 pg/mL led to 77% sensitivity
and 72% specificity. ROC: Receiver operating curve; Rpf: Resuscitation promoting factor; IGRA (interferon gamma release assay); AUC: area under
the curve
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which used several days stimulation and added costimu-
latory molecules such as CD28 and CD49d. In addition,
the participants’ younger age likely affected our observed
results. Because of the age-dependent maturation of the
immune system, children’s IFN-γ production tends to be
lower and the contribution of T-cells producing IFN-γ is
thought to be less compared to adults [4, 27, 28].
We additionally explored whether Rpf could discrim-
inate between infected and TB diseased children. Resus-
citation promoting factor B and D also induced a
significantly higher IFN-γ response in infected children
compared to TB diseased children. Similar results were
previously observed in adults [14, 16, 29]. In vitro,
RpfA-, B-, D-, and E-specific IFN-γ producing CD4+ T-
cells are less abundant in TB diseased patients compared
to infected individuals [29, 30]. These observations sup-
port the hypothesis that a Rpf-specific IFN-γ response
can discriminate infected individuals from TB diseased
cases. In our study population, Rpf responses did not
differ between those with TB disease and those without
TB disease (irrespective of infection status), due to the
similar Rpf response in children with TB disease com-
pared to uninfected children. Thus, our study does not
show discriminatory power of Rpf for TB disease per se,
it only shows a difference between children with infec-
tion and TB disease. This difference further confirms the
pattern of Rpf production during infection, which specif-
ically increase as the bacteria transit from latency to ac-
tive replication associated with progression to TB
disease [15, 16, 26]. With respect to the diagnosis of TB
disease, Rpf may only be useful when the infection status
of the patient is already ascertained. However, IFN-γ re-
sponses to Rpf might indicate whether individuals are at
risk of developing TB disease in the near future follow-
ing infection. Generally, the background IFN-γ produc-
tion was significantly higher in TB diseased children
compared to children without TB disease. The ROC-
curve analysis at 33.3 pg/mL cut-off could have identi-
fied children with TB disease from children without TB
disease with a sensitivity of 92.9%, but with a specificity
of 63.1%. Of note, this cut-off is relatively low, in par-
ticular when compared to the median (IQR) background
IFN-γ level of 23.3 (5.0–37.2) pg/mL. The higher IFN-γ
background response in TB diseased children might re-
flect the disease exacerbation profile that is accompanied
by non-specific inflammation and deserves further atten-
tion [28, 31].
Our study has some clear limitations regarding infec-
tion classification and the study population. We defined
MTBC infection by a single test, i.e., IGRA with EC-
fusion protein antigen. Although globally recognized as
a standard for TB screening, the EC-based IGRA test is
known to have lower sensitivity for M. africanum infec-
tion [6] and in children below 5 years of age [32]. In fact,
our study of Rpf-induced IFN-γ production levels in
IGRA+ and IGRA- children compares the immunogen-
icity of the EC and Rpf antigens. Therefore, our strict
separation of infected versus uninfected children purely
based on IGRA results should be considered with cau-
tion, as of course, there is no gold standard for MTBC
infection. However, assuming that our IGRA results
reflected the participants’ infection status more accur-
ately than the TST results that is confounded by BCG
vaccination and exposure to environmental mycobac-
teria [5], RpfB and D still hold promise for TB screening
in children. Another limitation of our study is the mod-
est sample size. This influenced the ROC-analyses,
which in turn had impact on the cut-off for IFN-γ re-
sponse. Another IFN-γ cut-off for RpfB and D would
have resulted in a different specificity and sensitivity,
which is why we strictly adhered to one method for
selecting the ideal cut-off: the Youden Index. Further-
more, all participants were part of a childhood TB
contact study, meaning that they had been exposed to
an adult smear-positive index TB case. Consequently,
no TB-unexposed negative controls were included.
Future work should include a larger control group
consisting of children with TB-like symptoms, but
who do not have TB disease and with confirmed al-
ternative diagnostics. This group of children is the
biggest confounder of TB disease diagnosis in chil-
dren based on clinical symptoms as these symptoms
resemble that of other paediatric illnesses occurring
in endemic regions [33]. Moreover, our study did not
include follow-up data on the progression from infec-
tion towards TB disease. Explicitly in the case of Rpf
responses, this shift warrants further investigation, be-
cause these antigens could offer new possibilities for
the prediction of progression to TB disease after ex-
posure [34]. Finally, we could not assess the effect of
MTBC strains diversity on the Rpf-specific immune
response because there were few bacilli culture posi-
tive sample. Future work would benefit from this add-
itional piece of information, to paint a more complete
picture of the possibilities and limitations of Rpf in
the field of TB.
Conclusions
Our study shows that immune responses to RpfB and D
can discriminate between household TB-exposed in-
fected and uninfected children with higher accuracy than
TST screening, with the EC-based IGRA taken as stand-
ard for MTBC infection. Additionally, both antigens in-
duce a lower IFN-γ response in children with TB disease
compared to infected children and thus warrant further
investigation as screening and diagnostic antigens for
childhood TB.
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